Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate HT-6184 in Healthy Subjects

NCT05447546
View directory record Official record
Conditions
Normal Healthy Subjects
Interventions
HT-6184, HT-6184 Placebo
Drug
Lead sponsor
Halia Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 25, 2026, 11:45 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 25, 2026, 11:45 AM EDT
Not listed Phase 1Phase 2 Interventional

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

NCT04205227
View directory record Official record
Conditions
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
Interventions
ENB003, Pembrolizumab
Drug
Lead sponsor
ENB Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 11:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retinal Fundus Camera Evaluation

NCT02293174
View directory record Official record
Conditions
Normal Healthy Subjects With no Known Ocular Diseases
Interventions
Topcon TRC-NW400, TRC-NW8, TRC-NW400, Canon-CR2, Zeiss Visucam PRO
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

NCT00590824
View directory record Official record
Conditions
Melanoma
Interventions
hu14.18-IL2
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
15 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

NCT00558103
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Long Beach, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma

NCT00061659
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
ABT-510 - Thrombospondin-1 mimetic
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Scottsdale, Arizona • Tucson, Arizona • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 25, 2026, 11:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

NCT02431260
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB054329 Monotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

NCT01648296
View directory record Official record
Conditions
Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
Interventions
[18F]FluorbetaOx
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

NCT00853320
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

NCT00437424
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Clleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash

NCT00891982
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CTGel/ BPO Wash, Soap Free Cleanser and CTGel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Coral Gables, Florida • Warren, Michigan • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Dose Response Study of Patients With Erythematous Rosacea

NCT01186068
View directory record Official record
Conditions
Erythematous (Type One) Rosacea
Interventions
V-101, vehicle
Drug · Other
Lead sponsor
Vicept Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
San Diego, California • Miami Beach, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 25, 2026, 11:45 AM EDT
Terminated Phase 1Phase 2 Interventional

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

NCT05154890
View directory record Official record
Conditions
Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
Interventions
Pegtarviliase IV, Pegtarviliase SC
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

NCT00550446
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Adalimumab, CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
22
States / cities
Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

NCT04678440
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
[18F]F-AraG Imaging
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 25, 2026, 11:45 AM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

NCT02843659
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
BMS-931699, BMS-986142, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Fullerton, California • Palo Alto, California • Sarasota, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

NCT00299546
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 25, 2026, 11:45 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 25, 2026, 11:45 AM EDT
Withdrawn Phase 2 Interventional

Fulvestrant + Neratinib In Breast Cancer

NCT04901299
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 25, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

NCT00680134
View directory record Official record
Conditions
Onychomycosis
Interventions
AN2690
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 25, 2026, 11:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Soleus H-Reflex in Different Sitting Postures

NCT01744899
View directory record Official record
Conditions
Compression of Spinal Nerve Root, Spinal Disorder, Low Back Pain
Interventions
Sitting posture
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 25, 2026, 11:45 AM EDT